In 2019, the U.S. Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (T-DXd) for the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior HER2-targeted regimens. Here, ERBB2 is linked to breast carcinoma.